Mouzam Profile picture
Dec 30, 2022 14 tweets 5 min read Read on X
Craftsman Automation

Diversifying Powertrain vertical: Interesting insights🧵

Sharing my notes on recent "Dr Axion India pvt." acquisition by #Craftsman

Buy price - ₹375 Cr
Axion FY21-22 Sales - ₹716 Cr
P/S - 0.5x

Adds >30% to the +₹2000 Cr Top line

Retweet♻️

1/n Image
Powertrain vertical (Cylinder Heads is part of this segment) - 52% of total revenue

Leading player for:
- CV (#1 position) - 54% revenue
- Off highway - 20% revenue
- Tractors (among top 3-4 outsourced players) - 18% revenue

Whereas, PV is only 8% only

2/n Image
Within Powertrain vertical, Cylinder heads & cylinder blocks make up the major chunk at 60% revenue

3/n Image
Cylinder Head:

SUV (PV) forms the biggest pie of the TAM in this product category where Craftsman didn't have any material presence as seen earlier.

4/n Image
Powertrain vertical particularly the cylinder block and cylinder heads are relatively high value & high margin products for Craftsman vis-à-vis transmission products due to the complexity involved in machining these products.

5/n Image
With that background lets look at Dr. Axion India business.

Incorporated in Dec 2006, it mfg. Cylinder heads for PV & CV

Its operations are supported by the South Korean R&D driven Parent co. DR Axion, who provides technical and operational expertise.

Strong Financials

6/n Image
The co. employs state of the art, automated production lines used by the parent.

Only 1 Mfg. plant - Chennai

Key customers:

PV:
- Hyundai Motor India Limited (HMIL) - 48% of total sales
- Kia Motors India Private Limited (KMIP)

CV:
Mahindra Heavy Engines Limited (MHEL)

7/n Image
Interestingly, its the sole supplier of Cylinder Head to both Hyundai & Kia in India (Almost 100%) Image
PV Market share based on total cars manufactured in India data.

- Hyundai - Top 3
- Kia - Gaining MS - Top 5

9/n Image
Facilitating M&M’s transition to aluminium engines

10/n Image
Financials:

- Sales volume grew by 39.0% YoY in 9M FY2022
- Sales growth at 49% CAGR FY19-22
- Synergies with Craftsman operations could potentially take the margins higher from here.

11/n ImageImage
Powertrain segment revenue share could potentially look drastically different with almost 700 Cr. getting added to PV segment with this acquisition, moving from 8% -> almost 40%

12/n Image
Craftsman mgt. guided for 20-25% CAGR growth for the next 3-4 years. This acquisition pushes it further up and opens its doors to Top PV OEMs and

13/n Image
14/n

Acquisition is expected to be completed before 31st March, 2023.

Sources: AR, Concalls, Credit reports, DRHP, Corporate announcements.

Disclosure: Invested, may exit at any point.
Not a buy/sell recommendation.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Mouzam

Mouzam Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @mmali09

Feb 2
#Turnaround
High level case study

Incredible transformation results in 20x returns in 1 year for this co.

Sales - more than doubled
OPM% from 3-4% to 12%
Interest exp - fell over a period due to deleveraging
PAT - from consistent loss to 600cr.

👍♻️🧵

1/ Image
2/ Huge Deleveraging:

Balance sheet transformations are some of the strongest signals of potential turnarounds Image
3/ Interesting fact about the co.

Its into DI pipes & Specialised Ferro Alloys

Their Ferro Alloy realisation is incredibly high & probably the highest in the industry at +1.70L/ton, here's comparison to Shyam & Sandur.

P.S - I don't track the industry closely

Image
Image
Image
Read 9 tweets
Feb 24, 2023
#Syrma #Kaynes #Dixon #PGEL

#EMS market is set to grow at +30% CAGR for at least next 5 years from ₹1,469Bn to ₹6,000Bn by FY27.

🧵 on some spl. business insights from Q3FY23 concall & other sources

@soicfinance @ishmohit1

1 can't miss this decadal opp.

Retweet♻️ & Like👍 Image
There are 2 models that business generally follow:

1. Low Value High Mix (LVHM) - eg. consumer
2. High Value Low Mix (HVLM) - eg. Industrial

This data suggests both type of businesses are set for long-term high growth. Image
This is a crowded space with Indian and large MNC players. However, the industry as a whole is set to grow exponentially and established players who can achieve scale & offer wider capabilities stand to win bigger + mgt. are saying they are just scratching the surface ryt now. Image
Read 27 tweets
Feb 15, 2023
#SJS

Interesting development: Partnered with #Foxconn in 2W EV

- Foxconn is a large key component supplier to many OEMs globally
- Focus is mass production
- Achieve economies of scale = cheaper production cost per unit
- Fully integrated solutions

So why is this imp ?🧵

1/10
2/

2021 news - Foxconn aims to build EV factories in Europe and India by 2024. Not sure if there has been any developments on ground but it gives an indication towards their ambition

asia.nikkei.com/Business/Techn…
3/

Longtime iPhone assembler Foxconn has been stepping up efforts to expand its presence in the booming EV industry since its new chairman assumed position in mid 2019.

Their chairman was in India last year discussing opportunity in India.
Read 10 tweets
Feb 11, 2023
#Specialsituation #Spinoff #Demerger #AARTIPHARM🧵

- Business overview
- Financials
- Valuations
- 1 year Concall highlights (Q1 FY22 to Q1FY23)

Took long to compile this
Retweet♻️ & Like👍

For wider reach
@soicfinance @itsTarH @Shubham_TLI @ValueEducator @Gautam__Baid

1/14 Image
2/ Co. overview
Image
Image
3/ Segments:

APIs & Intermediates for innovators & generic firms for a variety of applications like anti-cancer, anti-asthmatic, antihypertensive, oncology medicines.

Xanthine derivatives are used for beverages, as well as nutraceutical and other pharma applications. Image
Read 20 tweets
Jan 2, 2022
1/ Its been a while since I last posted🧵

But when your mentor asks you to read a business you oblige. Thanks @ishmohit1, please add your insights if you find any gaps.

#Taskus 🇺🇸 $TASK
"Outsourcing reimagined for the innovation age"
🔥60% Revenue CAGR over past 4 years
2/ Background: Founded in 2008 during recession by 2 high school best friends, Jasper Weir & Bryce Maddock
3/ While all major competitors in the industry were occupied serving traditional telco clients, they focused efforts on the emerging digital economy. Most clients have 3 things in common: they are truly customer obsessed, they've grown faster than nearly every other company
Read 63 tweets
Sep 21, 2021
#Heranba Anti-Thesis (Regulatory Risk)

1/ Started reading about the co. since it has one of the best ROCE in the AgroChem Industry with decent margins and reasonably valued.

Although growth levers are in place one long term risk stood out for me. Here's a 🧵on it

#Agrochemical
2/ About the co. - Great export biz - almost 50% Revenue from sales in 60+ countries (Exports). No client concentration risk with top 10 making 23% sales only.
3/ Leading forward integrated domestic producer of Synthetic pyrethroids & has has presence across its value chain (intermediates, technicals & formulations).
Read 16 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(